The first FDA-approved* digital therapeutic for amblyopia.
*De Novo granted in Oct 2021.
Kids Watch TV as Treatment
Say goodbye to eye patches and eye drops — the future of amblyopia treatment is here. With Luminopia, children can watch TV to improve their vision. Whether it’s Spongebob, Wild Kratts, or Sesame Street, all kids have to do is pick a video, sit back, and watch. Our software algorithms take care of the rest, by presenting the images differently to each eye and stimulating parts of the brain responsible for vision.
Luminopia is Simple, Engaging, And Effective
For physicians, all you have to do is send an e-Rx or fax prescription to our retail pharmacy partner and we will take care of the rest -- no need to think about inventory, payment, or anything else. For patients, we provide everything you need to get started, including a VR headset with access to the treatment software.
Patients can choose from over 700 hours of popular TV shows and movies to watch during treatment, which is why compliance with Luminopia was around double that of patching in our clinical trials. The recommended dose is lighter too -- it’s 1 hour per day, 6 days per week.
Luminopia is based in cutting-edge neuroscience and has been studied in three clinical trials, with similar rigor as a new pharmaceutical product. Children can experience significant vision benefit as early as a month, and the therapy works in both new patients and those that have been through patching or atropine drops.
Rooted in Science
Traditional therapies like patching and atropine drops punish the stronger eye to force the brain to pay attention to the weaker eye. But they don’t teach the eyes how to work together properly.
Luminopia is different. Luminopia is built on decades of cutting-edge research done by leading clinicians and neuroscientists at Boston Children’s Hospital and MIT. Our software algorithms rebalance input between the eyes, and encourage the brain to combine the images from both eyes. We harness the power of VR headsets to deliver treatment within a controlled environment with no distractions.
View Supporting Literature
Luminopia has been validated through a similar development process as a new pharmaceutical product. The technology has been evaluated in 3 clinical trials, with 200+ patients at more than 20 hospitals and research sites across the US, including a gold standard, randomized controlled Phase 3 trial which demonstrated the safety and efficacy of the therapy for children aged 4-7 years.
compliance with the full dose of
1 hr/day, 6 days/week over
of kids can read two or
more lines on an eye chart
Our Clinical Partners
The technology behind Luminopia was developed and tested at leading academic institutions across the country.
Our Media partners
We've partnered with several of the most beloved entertainment companies to create a captivating experience for children.